Cue Biopharma (CUE) Q2 2024 earnings summary

Executive summary

• Strategic corporate restructuring and a 25% workforce reduction were implemented to reduce capital requirements, enhance productivity, and prioritize autoimmune programs (CUE-401, CUE-501), while retaining oncology programs as clinical data matures.

• Lead autoimmune program CUE-401, in partnership with Ono, is advancing toward lead candidate selection in early 2025, with CUE-501 also prioritized for development.

• Oncology programs CUE-101 and CUE-102 continue to show robust clinical benefit and survival improvements in head and neck and other cancers, with CUE-101 demonstrating improved ORR and OS compared to historical standards.

• Ongoing pursuit of third-party partnerships for further development and funding of both oncology and autoimmune assets.

• Business model and strategic focus aim to optimize capital and value creation while managing capital access risk.

Financial highlights

• Collaboration revenue rose to $2.7M for Q2 2024 (up $1.3M YoY), mainly from the Ono agreement; six-month revenue was $4.4M (up $2.8M YoY).

• Net loss for Q2 2024 was $10.2M, improved from $13.2M in Q2 2023; six-month net loss was $22.5M, improved from $26.3M YoY.

• Cash and cash equivalents were $30.0M as of June 30, 2024, down from $48.5M at year-end 2023.

• Operating expenses, including R&D and G&A, decreased year-over-year.

• Operational cash burn reduced from ~$40M/year to ~$30M/year, extending runway to mid-2025.

Outlook and guidance

• Existing cash is expected to fund operations through Q2 2025; additional capital will be needed to continue operations beyond that period.

• Anticipated milestones include lead selection for CUE-401, strategic partnering for CUE-501, and ongoing data maturation from oncology trials.

• Phase 2 trial for CUE-101 is contingent on securing alternative capital sources.

• Updates on clinical progress planned for SITC in November.